Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495276 | 1.00 | ALOX15 (0.34) | ALOX15KMT2AMEN1HTTSMO | |
| SCHEMBL6495272 | 0.82 | ALOX15 (0.34) | ALOX15KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL6495090 | 0.81 | MEN1 (0.38) | ALOX15KMT2AMEN1HTTGAA | |
| SCHEMBL6505067 | 0.75 | ALDH1A1 (0.45) | KMT2AMEN1HTTGAAALDH1A1 | |
| SCHEMBL6496201 | 0.75 | POLB (0.54) | KMT2AMEN1HTTGAAALDH1A1 | |
| SCHEMBL6502530 | 0.74 | KMT2A (0.43) | KMT2AMEN1SMOGAAALDH1A1 | |
| SCHEMBL6494226 | 0.74 | SMO (0.41) | KMT2AMEN1SMOGAAALDH1A1 | |
| SCHEMBL6501118 | 0.74 | MEN1 (0.43) | KMT2AMEN1HTTSMOGAA | |
| SCHEMBL6503948 | 0.73 | ROCK2 (0.40) | ALOX15KMT2AMEN1HTTSMO | |
| SCHEMBL6503078 | 0.73 | ROCK2 (0.40) | ALOX15KMT2AMEN1HTTSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | claimed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | claimed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | ALOX15 1/4885KMT2A 2042/4885MEN1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.